QUVIVIQ Trademark

Trademark Overview


On Wednesday, July 6, 2022, a trademark application was filed for QUVIVIQ with the United States Patent and Trademark Office. The USPTO has given the QUVIVIQ trademark a serial number of 79350361. The federal status of this trademark filing is REGISTERED as of Tuesday, April 2, 2024. This trademark is owned by Idorsia Pharmaceuticals Ltd. The QUVIVIQ trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations intended for the prevention or treatment of cardiovascular diseases, hypertension, cerebral haemorrhages and sequela thereof, kidney diseases, pulmonary diseases, fibrotic diseases, cystic fibrosis, inflammatory diseases, allergy diseases, autoimmune diseases and disorders, neurodegenerative diseases and disorders, neurological diseases and disorders, central nervous system diseases and disorders, dementia, insomnia, anxiety disorders, addictions, eating disorders, epilepsy, metabolic disorders, diabetes, glycolipid storage diseases, Fabry disease and Fabry disease symptoms and sequela, infectious diseases and cancer
quviviq

General Information


Serial Number79350361
Word MarkQUVIVIQ
Filing DateWednesday, July 6, 2022
Status700 - REGISTERED
Status DateTuesday, April 2, 2024
Registration Number7341596
Registration DateTuesday, April 2, 2024
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 16, 2024

Trademark Statements


Description of MarkThe mark consists of the stylized wording "QUVIVIQ" with five circles formingan arch over the "VIV" letters in the mark.
Goods and ServicesPharmaceutical preparations intended for the prevention or treatment of cardiovascular diseases, hypertension, cerebral haemorrhages and sequela thereof, kidney diseases, pulmonary diseases, fibrotic diseases, cystic fibrosis, inflammatory diseases, allergy diseases, autoimmune diseases and disorders, neurodegenerative diseases and disorders, neurological diseases and disorders, central nervous system diseases and disorders, dementia, insomnia, anxiety disorders, addictions, eating disorders, epilepsy, metabolic disorders, diabetes, glycolipid storage diseases, Fabry disease and Fabry disease symptoms and sequela, infectious diseases and cancer

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, September 23, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameIdorsia Pharmaceuticals Ltd
Party Type30 - Original Registrant
Legal Entity Type25 - NOT AVAILABLE
AddressCH

Party NameIdorsia Pharmaceuticals Ltd
Party Type20 - Owner at Publication
Legal Entity Type25 - NOT AVAILABLE
AddressCH

Party NameIdorsia Pharmaceuticals Ltd
Party Type10 - Original Applicant
Legal Entity Type25 - NOT AVAILABLE
AddressCH

Trademark Events


Event DateEvent Description
Thursday, March 2, 2023CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED
Thursday, September 22, 2022SN ASSIGNED FOR SECT 66A APPL FROM IB
Friday, September 23, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, September 27, 2022APPLICATION FILING RECEIPT MAILED
Monday, February 13, 2023CORRECTION TRANSACTION RECEIVED FROM IB
Thursday, April 20, 2023ASSIGNED TO EXAMINER
Wednesday, April 26, 2023NON-FINAL ACTION WRITTEN
Thursday, April 27, 2023NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Thursday, December 7, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Saturday, June 10, 2023REFUSAL PROCESSED BY MPU
Saturday, June 10, 2023NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Tuesday, July 4, 2023REFUSAL PROCESSED BY IB
Thursday, December 7, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, December 7, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Thursday, December 7, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, December 7, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, December 7, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, December 7, 2023TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Thursday, December 7, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, December 8, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, December 11, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, December 27, 2023NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, December 27, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, December 27, 2023NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Saturday, January 13, 2024NOTIFICATION PROCESSED BY IB
Tuesday, January 16, 2024PUBLISHED FOR OPPOSITION
Tuesday, January 16, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 2, 2024REGISTERED-PRINCIPAL REGISTER
Tuesday, April 2, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED
Wednesday, July 3, 2024FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB